nach oben

Current Anesthesiology Reports

Erschienen in:

11.11.2019 | Thoracic Anesthesia (T Schilling, Section Editor)

Pulmonary Hypertension and Thoracic Surgery: Impact and Treatment Options

verfasst von: Loren Francis, Stephanie Whitener, Jared McKinnon, George Whitener

Erschienen in: Current Anesthesiology Reports | Ausgabe 4/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

The purpose of this paper is to review updates to the definition of pulmonary hypertension (PH), its diagnosis, and management. New treatment options, the role of mechanical support, outcome studies, and intraoperative management will be emphasized.

Recent Findings

The definition of PH has been recently changed, with a decrease in the qualifying mean pulmonary artery pressure and the addition of pulmonary vascular resistance. There have been minor changes to PH classifications. Some new medications are available to treat PH, and new associations between drugs and PH have been discovered. Recommended intraoperative management strategies are included. Updated outcome studies are discussed, as well as the potential role of mechanical devices for managing PH patients during or after thoracic surgery.

Summary

Pulmonary hypertension (PH) comprises a complex group of pathologies that can be difficult to identify and care for perioperatively. Caring for patients with PH requires cardiovascular management expertise, familiarity with medicines used to treat PH, and the ability to accurately interpret diagnostic data and hemodynamic monitors.

Badesch DB, Champion HC, Sanchez MA, Hoeper MM, Loyd JE, Manes A, et al. Diagnosis and assessment of pulmonary arterial hypertension. J Am Coll Cardiol. 2009;54(1 Suppl):S55–66. https://doi.org/10.1016/j.jacc.2009.04.011.CrossRefPubMed

•• Simonneau G, Montani D, Celermajer DS, Denton CP, Gatzoulis MA, Krowka M, et al. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respir J. 2019;53(1). https://doi.org/10.1183/13993003.01913-2018Recently published updated hemodynamic definitions and classifications of PH. This paper discusses the 6^thWorld Symposium on PH which met in 2018 and changed the parameters of PH by decreasing the mean PA pressure threshold and adding the component of pulmonary vascular resistance. Two new subgroups were added to the PH classification system.

Kovacs G, Berghold A, Scheidl S, Olschewski H. Pulmonary arterial pressure during rest and exercise in healthy subjects: a systematic review. Eur Respir J. 2009;34(4):888–94. https://doi.org/10.1183/09031936.00145608.CrossRefPubMed

Douschan P, Kovacs G, Avian A, Foris V, Gruber F, Olschewski A, et al. Mild elevation of pulmonary arterial pressure as a predictor of mortality. Am J Respir Crit Care Med. 2018;197(4):509–16. https://doi.org/10.1164/rccm.201706-1215OC.CrossRefPubMed

Coghlan JG, Wolf M, Distler O, Denton CP, Doelberg M, Harutyunova S, et al. Incidence of pulmonary hypertension and determining factors in patients with systemic sclerosis. Eur Respir J. 2018;51(4). https://doi.org/10.1183/13993003.01197-2017.

Valerio CJ, Schreiber BE, Handler CE, Denton CP, Coghlan JG. Borderline mean pulmonary artery pressure in patients with systemic sclerosis: transpulmonary gradient predicts risk of developing pulmonary hypertension. Arthritis Rheum. 2013;65(4):1074–84. https://doi.org/10.1002/art.37838.CrossRefPubMed

Montani D, Bergot E, Gunther S, Savale L, Bergeron A, Bourdin A, et al. Pulmonary arterial hypertension in patients treated by dasatinib. Circulation. 2012;125(17):2128–37. https://doi.org/10.1161/circulationaha.111.079921.CrossRefPubMed

Weatherald J, Chaumais MC, Savale L, Jais X, Seferian A, Canuet M, et al. Long-term outcomes of dasatinib-induced pulmonary arterial hypertension: a population-based study. Eur Respir J. 2017;50(1). https://doi.org/10.1183/13993003.00217-2017.

Zamanian RT, Hedlin H, Greuenwald P, Wilson DM, Segal JI, Jorden M, et al. Features and outcomes of methamphetamine-associated pulmonary arterial hypertension. Am J Respir Crit Care Med. 2018;197(6):788–800. https://doi.org/10.1164/rccm.201705-0943OC.CrossRefPubMedPubMedCentral

10.

Nishio M, Hirooka K, Doi Y. Chinese herbal drug natural indigo may cause pulmonary artery hypertension. Eur Heart J. 2016;37(25):1992. https://doi.org/10.1093/eurheartj/ehw090.CrossRefPubMed

11.

Savale L, Chaumais MC, Montani D, Jais X, Hezode C, Antonini TM, et al. Direct-acting antiviral medications for hepatitis C virus infection and pulmonary arterial hypertension. Chest. 2016;150(1):256–8. https://doi.org/10.1016/j.chest.2016.04.031.CrossRefPubMed

12.

Hickey PM, Thompson AA, Charalampopoulos A, Elliot CA, Hamilton N, Kiely DG, et al. Bosutinib therapy resulting in severe deterioration of pre-existing pulmonary arterial hypertension. Eur Respir J. 2016;48(5):1514–6. https://doi.org/10.1183/13993003.01004-2016.CrossRefPubMed

13.

Sun XG, Hansen JE, Oudiz RJ, Wasserman K. Pulmonary function in primary pulmonary hypertension. J Am Coll Cardiol. 2003;41(6):1028–35. https://doi.org/10.1016/s0735-1097(02)02964-9.CrossRefPubMed

14.

Jilwan FN, Escourrou P, Garcia G, Jais X, Humbert M, Roisman G. High occurrence of hypoxemic sleep respiratory disorders in precapillary pulmonary hypertension and mechanisms. Chest. 2013;143(1):47–55. https://doi.org/10.1378/chest.11-3124.CrossRefPubMed

15.

Boisen ML, Rao VK, Kolarczyk L, Hayanga HK, Gelzinis TA. The year in thoracic anesthesia: selected highlights from 2016. J Cardiothorac Vasc Anesth. 2017;31(3):791–9. https://doi.org/10.1053/j.jvca.2017.02.182.CrossRefPubMed

16.

• Augustine DX, Coates-Bradshaw LD, Willis J, Harkness A, Ring L, Grapsa J, et al. Echocardiographic assessment of pulmonary hypertension: a guideline protocol from the British Society of Echocardiography. Echo Res Pract. 2018;5(3):G11–g24. https://doi.org/10.1530/erp-17-0071This paper discusses guidelines for assessing PH by echocardiogram, including common measurements and how to obtain them as well as correlating them clinically and pointing out potential sources of error. CrossRefPubMedPubMedCentral

17.

Keir GJ, Wort SJ, Kokosi M, George PM, Walsh SLF, Jacob J, et al. Pulmonary hypertension in interstitial lung disease: Limitations of echocardiography compared to cardiac catheterization. Respirology. 2018;23(7):687–94. https://doi.org/10.1111/resp.13250.CrossRefPubMed

18.

• Leuchte HH, Ten Freyhaus H, Gall H, Halank M, Hoeper MM, Kaemmerer H, et al. Risk stratification strategy and assessment of disease progression in patients with pulmonary arterial hypertension: Updated Recommendations from the Cologne Consensus Conference 2018. Int J Cardiol. 2018;272s:20–9. https://doi.org/10.1016/j.ijcard.2018.08.084This paper details updated recommendations from the 2019 Cologne Consensus Conference and discusses in detail a recommended risk stratification strategy for PH patients. CrossRefPubMed

19.

•• Galie N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J. 2016;37(1):67–119. https://doi.org/10.1093/eurheartj/ehv317These updated guidelines discuss diagnosis and treatment of PH. CrossRefPubMed

20.

Tedford RJ, Beaty CA, Mathai SC, Kolb TM, Damico R, Hassoun PM, et al. Prognostic value of the pre-transplant diastolic pulmonary artery pressure-to-pulmonary capillary wedge pressure gradient in cardiac transplant recipients with pulmonary hypertension. J Heart Lung Transplant. 2014;33(3):289–97. https://doi.org/10.1016/j.healun.2013.11.008.CrossRefPubMed

21.

Swift AJ, Capener D, Johns C, Hamilton N, Rothman A, Elliot C, et al. Magnetic resonance imaging in the prognostic evaluation of patients with pulmonary arterial hypertension. Am J Respir Crit Care Med. 2017;196(2):228–39. https://doi.org/10.1164/rccm.201611-2365OC.CrossRefPubMedPubMedCentral

22.

Boucly A, Weatherald J, Savale L, Jais X, Cottin V, Prevot G, et al. Risk assessment, prognosis and guideline implementation in pulmonary arterial hypertension. Eur Respir J. 2017;50(2). https://doi.org/10.1183/13993003.00889-2017.

23.

Kylhammar D, Kjellstrom B, Hjalmarsson C, Jansson K, Nisell M, Soderberg S, et al. A comprehensive risk stratification at early follow-up determines prognosis in pulmonary arterial hypertension. Eur Heart J. 2018;39(47):4175–81. https://doi.org/10.1093/eurheartj/ehx257.CrossRefPubMed

24.

Hoeper MM, Kramer T, Pan Z, Eichstaedt CA, Spiesshoefer J, Benjamin N, et al. Mortality in pulmonary arterial hypertension: prediction by the 2015 European pulmonary hypertension guidelines risk stratification model. Eur Respir J. 2017;50(2). https://doi.org/10.1183/13993003.00740-2017.

25.

Gibbons Kroeker CA, Adeeb S, Shrive NG, Tyberg JV. Compression induced by RV pressure overload decreases regional coronary blood flow in anesthetized dogs. Am J Physiol Heart Circ Physiol. 2006;290(6):H2432–8. https://doi.org/10.1152/ajpheart.01140.2005.CrossRefPubMed

26.

Vlahakes GJ, Turley K, Hoffman JI. The pathophysiology of failure in acute right ventricular hypertension: hemodynamic and biochemical correlations. Circulation. 1981;63(1):87–95. https://doi.org/10.1161/01.cir.63.1.87.CrossRefPubMed

27.

Zylkowska J, Kurzyna M, Florczyk M, Burakowska B, Grzegorczyk F, Burakowski J, et al. Pulmonary artery dilatation correlates with the risk of unexpected death in chronic arterial or thromboembolic pulmonary hypertension. Chest. 2012;142(6):1406–16. https://doi.org/10.1378/chest.11-2794.CrossRefPubMed

28.

Rubini A. Effect of perfusate temperature on pulmonary vascular resistance and compliance by arterial and venous occlusion in the rat. Eur J Appl Physiol. 2005;93(4):435–9. https://doi.org/10.1007/s00421-004-1235-x.CrossRefPubMed

29.

Sandham JD, Hull RD, Brant RF, Knox L, Pineo GF, Doig CJ, et al. A randomized, controlled trial of the use of pulmonary-artery catheters in high-risk surgical patients. N Engl J Med. 2003;348(1):5–14. https://doi.org/10.1056/NEJMoa021108.CrossRefPubMed

30.

Valentine RJ, Duke ML, Inman MH, Grayburn PA, Hagino RT, Kakish HB, et al. Effectiveness of pulmonary artery catheters in aortic surgery: a randomized trial. J Vasc Surg. 1998;27(2):203–11 discussion 11-2.CrossRef

31.

Rajaram SS, Desai NK, Kalra A, Gajera M, Cavanaugh SK, Brampton W, et al. Pulmonary artery catheters for adult patients in intensive care. Cochrane Database Syst Rev. 2013;2:CD003408. https://doi.org/10.1002/14651858.CD003408.pub3.CrossRef

32.

Schwann NM, Hillel Z, Hoeft A, Barash P, Mohnle P, Miao Y, et al. Lack of effectiveness of the pulmonary artery catheter in cardiac surgery. Anesth Analg. 2011;113(5):994–1002. https://doi.org/10.1213/ANE.0b013e31822c94a8.CrossRefPubMed

33.

Forrest P. Anaesthesia and right ventricular failure. Anaesth Intensive Care. 2009;37(3):370–85. https://doi.org/10.1177/0310057X0903700314.CrossRefPubMed

34.

Lee M, Curley GF, Mustard M, Mazer CD. The Swan-Ganz catheter remains a critically important component of monitoring in cardiovascular critical care. Can J Cardiol. 2017;33(1):142–7. https://doi.org/10.1016/j.cjca.2016.10.026.CrossRefPubMed

35.

Ashes C, Roscoe A. Transesophageal echocardiography in thoracic anesthesia: pulmonary hypertension and right ventricular function. Curr Opin Anaesthesiol. 2015;28(1):38–44. https://doi.org/10.1097/aco.0000000000000138.CrossRefPubMed

36.

Sullivan B, Puskas F, Fernandez-Bustamante A. Transesophageal echocardiography in noncardiac thoracic surgery. Anesthesiol Clin. 2012;30(4):657–69. https://doi.org/10.1016/j.anclin.2012.08.007.CrossRefPubMed

37.

Hahn RT, Abraham T, Adams MS, Bruce CJ, Glas KE, Lang RM, et al. Guidelines for performing a comprehensive transesophageal echocardiographic examination: recommendations from the American Society of Echocardiography and the Society of Cardiovascular Anesthesiologists. J Am Soc Echocardiogr. 2013;26(9):921–64. https://doi.org/10.1016/j.echo.2013.07.009.CrossRefPubMed

38.

Pilkington SA, Taboada D, Martinez G. Pulmonary hypertension and its management in patients undergoing non-cardiac surgery. Anaesthesia. 2015;70(1):56–70. https://doi.org/10.1111/anae.12831.CrossRefPubMed

39.

Salmasi V, Maheshwari K, Yang D, Mascha EJ, Singh A, Sessler DI, et al. Relationship between intraoperative hypotension, defined by either reduction from baseline or absolute thresholds, and acute kidney and myocardial injury after noncardiac surgery: a retrospective cohort analysis. Anesthesiology. 2017;126(1):47–65. https://doi.org/10.1097/ALN.0000000000001432.CrossRefPubMed

40.

Strumpher J, Jacobsohn E. Pulmonary hypertension and right ventricular dysfunction: physiology and perioperative management. J Cardiothorac Vasc Anesth. 2011;25(4):687–704. https://doi.org/10.1053/j.jvca.2011.02.022.CrossRefPubMed

41.

Gooding JM, Dimick AR, Tavakoli M, Corssen G. A physiologic analysis of cardiopulmonary responses to ketamine anesthesia in noncardiac patients. Anesth Analg. 1977;56(6):813–6.PubMed

42.

Spotoft H, Korshin JD, Sorensen MB, Skovsted P. The cardiovascular effects of ketamine used for induction of anaesthesia in patients with valvular heart disease. Can Anaesth Soc J. 1979;26(6):463–7.CrossRef

43.

Kaye AD, Banister RE, Fox CJ, Ibrahim IN, Nossaman BD. Analysis of ketamine responses in the pulmonary vascular bed of the cat. Crit Care Med. 2000;28(4):1077–82. https://doi.org/10.1097/00003246-200004000-00028.CrossRefPubMed

44.

Waxman K, Shoemaker WC, Lippmann M. Cardiovascular effects of anesthetic induction with ketamine. Anesth Analg. 1980;59(5):355–8.CrossRef

45.

White PF, Way WL, Trevor AJ. Ketamine--its pharmacology and therapeutic uses. Anesthesiology. 1982;56(2):119–36. https://doi.org/10.1097/00000542-198202000-00007.CrossRefPubMed

46.

Bruder EA, Ball IM, Ridi S, Pickett W, Hohl C. Single induction dose of etomidate versus other induction agents for endotracheal intubation in critically ill patients. Cochrane Database Syst Rev. 2015;1:CD010225. https://doi.org/10.1002/14651858.CD010225.pub2.CrossRefPubMed

47.

Kaye AD, Hoover JM, Kaye AJ, Ibrahim IN, Fox C, Bajwa A, et al. Morphine, opioids, and the feline pulmonary vascular bed. Acta Anaesthesiol Scand. 2008;52(7):931–7. https://doi.org/10.1111/j.1399-6576.2008.01595.x.CrossRefPubMed

48.

Lohser J, Slinger P. Lung injury after one-lung ventilation: a review of the pathophysiologic mechanisms affecting the ventilated and the collapsed lung. Anesth Analg. 2015;121(2):302–18. https://doi.org/10.1213/ANE.0000000000000808.CrossRefPubMed

49.

Schilling T, Kozian A, Huth C, Buhling F, Kretzschmar M, Welte T, et al. The pulmonary immune effects of mechanical ventilation in patients undergoing thoracic surgery. Anesth Analg. 2005;101(4):957–65, table of contents. https://doi.org/10.1213/01.ane.0000172112.02902.77.CrossRefPubMed

50.

El Tahan MR, Pasin L, Marczin N, Landoni G. Impact of low tidal volumes during one-lung ventilation. A meta-analysis of randomized controlled trials. J Cardiothorac Vasc Anesth. 2017;31(5):1767–73. https://doi.org/10.1053/j.jvca.2017.06.015.CrossRefPubMed

51.

Blank RS, Colquhoun DA, Durieux ME, Kozower BD, McMurry TL, Bender SP, et al. Management of one-lung ventilation: impact of tidal volume on complications after thoracic surgery. Anesthesiology. 2016;124(6):1286–95. https://doi.org/10.1097/ALN.0000000000001100.CrossRefPubMed

52.

Nielsen DV, Torp-Pedersen C, Skals RK, Gerds TA, Karaliunaite Z, Jakobsen CJ. Intraoperative milrinone versus dobutamine in cardiac surgery patients: a retrospective cohort study on mortality. Crit Care. 2018;22(1):51. https://doi.org/10.1186/s13054-018-1969-1.CrossRefPubMedPubMedCentral

53.

King JB, Shah RU, Sainski-Nguyen A, Biskupiak J, Munger MA, Bress AP. Effect of inpatient dobutamine versus milrinone on out-of-hospital mortality in patients with acute decompensated heart failure. Pharmacotherapy. 2017;37(6):662–72. https://doi.org/10.1002/phar.1939.CrossRefPubMed

54.

Leier CV, Heban PT, Huss P, Bush CA, Lewis RP. Comparative systemic and regional hemodynamic effects of dopamine and dobutamine in patients with cardiomyopathic heart failure. Circulation. 1978;58(3 Pt 1):466–75. https://doi.org/10.1161/01.cir.58.3.466.CrossRefPubMed

55.

Bradford KK, Deb B, Pearl RG. Combination therapy with inhaled nitric oxide and intravenous dobutamine during pulmonary hypertension in the rabbit. J Cardiovasc Pharmacol. 2000;36(2):146–51. https://doi.org/10.1097/00005344-200008000-00002.CrossRefPubMed

56.

Levy B, Clere-Jehl R, Legras A, Morichau-Beauchant T, Leone M, Frederique G, et al. Epinephrine versus norepinephrine for cardiogenic shock after acute myocardial infarction. J Am Coll Cardiol. 2018;72(2):173–82. https://doi.org/10.1016/j.jacc.2018.04.051.CrossRefPubMed

57.

Kwak YL, Lee CS, Park YH, Hong YW. The effect of phenylephrine and norepinephrine in patients with chronic pulmonary hypertension*. Anaesthesia. 2002;57(1):9–14. https://doi.org/10.1046/j.1365-2044.2002.02324.x.CrossRefPubMed

58.

Leather HA, Segers P, Berends N, Vandermeersch E, Wouters PF. Effects of vasopressin on right ventricular function in an experimental model of acute pulmonary hypertension. Crit Care Med. 2002;30(11):2548–52. https://doi.org/10.1097/00003246-200211000-00024.CrossRefPubMed

59.

Evora PR, Pearson PJ, Schaff HV. Arginine vasopressin induces endothelium-dependent vasodilatation of the pulmonary artery. V1-receptor-mediated production of nitric oxide. Chest. 1993;103(4):1241–5. https://doi.org/10.1378/chest.103.4.1241.CrossRefPubMed

60.

Sugawara Y, Mizuno Y, Oku S, Goto T. Effects of vasopressin during a pulmonary hypertensive crisis induced by acute hypoxia in a rat model of pulmonary hypertension. Br J Anaesth. 2019;122(4):437–47. https://doi.org/10.1016/j.bja.2019.01.014.CrossRefPubMedPubMedCentral

61.

Gordon AC, Wang N, Walley KR, Ashby D, Russell JA. The cardiopulmonary effects of vasopressin compared with norepinephrine in septic shock. Chest. 2012;142(3):593–605. https://doi.org/10.1378/chest.11-2604.CrossRefPubMed

62.

Hajjar LA, Vincent JL, Barbosa Gomes Galas FR, Rhodes A, Landoni G, Osawa EA, et al. Vasopressin versus norepinephrine in patients with vasoplegic shock after cardiac surgery: The VANCS Randomized Controlled Trial. Anesthesiology. 2017;126(1):85–93. https://doi.org/10.1097/ALN.0000000000001434.CrossRefPubMed

63.

Price LC, Wort SJ, Finney SJ, Marino PS, Brett SJ. Pulmonary vascular and right ventricular dysfunction in adult critical care: current and emerging options for management: a systematic literature review. Crit Care. 2010;14(5):R169. https://doi.org/10.1186/cc9264.CrossRefPubMedPubMedCentral

64.

Manohar MV, Vaidya A, Bakshi S. Revisiting epidural anaesthesia in a parturient with idiopathic pulmonary hypertension posted for caesarean section. Indian J Anaesth. 2014;58(2):235–6. https://doi.org/10.4103/0019-5049.130864.CrossRefPubMedPubMedCentral

65.

Decoene C, Bourzoufi K, Moreau D, Narducci F, Crepin F, Krivosic-Horber R. Use of inhaled nitric oxide for emergency Cesarean section in a woman with unexpected primary pulmonary hypertension. Can J Anaesth. 2001;48(6):584–7. https://doi.org/10.1007/BF03016836.CrossRefPubMed

66.

Bildirici I, Shumway JB. Intravenous and inhaled epoprostenol for primary pulmonary hypertension during pregnancy and delivery. Obstet Gynecol. 2004;103(5 Pt 2):1102–5. https://doi.org/10.1097/01.AOG.0000121826.75294.39.CrossRefPubMed

67.

Horlocker TT, Vandermeuelen E, Kopp SL, Gogarten W, Leffert LR, Benzon HT. Regional anesthesia in the patient receiving antithrombotic or thrombolytic therapy: American Society of Regional Anesthesia and Pain Medicine Evidence-Based Guidelines (Fourth Edition). Reg Anesth Pain Med. 2018;43(3):263–309. https://doi.org/10.1097/AAP.0000000000000763.CrossRefPubMed

68.

Ghofrani HA, D'Armini AM, Grimminger F, Hoeper MM, Jansa P, Kim NH, et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. N Engl J Med. 2013;369(4):319–29. https://doi.org/10.1056/NEJMoa1209657.CrossRefPubMed

69.

Mitchell JA, Ahmetaj-Shala B, Kirkby NS, Wright WR, Mackenzie LS, Reed DM, et al. Role of prostacyclin in pulmonary hypertension. Glob Cardiol Sci Pract. 2014;2014(4):382–93. https://doi.org/10.5339/gcsp.2014.53.CrossRefPubMedPubMedCentral

70.

Sitbon O, Humbert M, Nunes H, Parent F, Garcia G, Herve P, et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol. 2002;40(4):780–8. https://doi.org/10.1016/s0735-1097(02)02012-0.CrossRefPubMed

71.

Wirth JA, Palevsky HI. Prostacyclin therapy for pulmonary arterial hypertension evolves again with the development of an implantable delivery system. Chest. 2017;152(6):1100–2. https://doi.org/10.1016/j.chest.2017.07.006.CrossRefPubMed

72.

Medarov BI, Judson MA. The role of calcium channel blockers for the treatment of pulmonary arterial hypertension: How much do we actually know and how could they be positioned today? Respir Med. 2015;109(5):557–64. https://doi.org/10.1016/j.rmed.2015.01.004.CrossRefPubMed

73.

Gaffuri M, Cristofaletti A, Mansoldo C, Biban P. Acute onset of bilateral visual loss during sildenafil therapy in a young infant with congenital heart disease. BMJ Case Rep. 2014;2014. https://doi.org/10.1136/bcr-2014-204262.

74.

Pulido T, Adzerikho I, Channick RN, Delcroix M, Galie N, Ghofrani HA, et al. Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med. 2013;369(9):809–18. https://doi.org/10.1056/NEJMoa1213917.CrossRefPubMed

75.

Rose-Jones LJ, McLaughlin VV. Pulmonary hypertension: types and treatments. Curr Cardiol Rev. 2015;11(1):73–9.CrossRef

76.

Bartolome S, Hoeper MM, Klepetko W. Advanced pulmonary arterial hypertension: mechanical support and lung transplantation. Eur Respir Rev. 2017;26(146). https://doi.org/10.1183/16000617.0089-2017.

77.

Smilowitz NR, Armanious A, Bangalore S, Ramakrishna H, Berger JS. Cardiovascular outcomes of patients with pulmonary hypertension undergoing noncardiac surgery. Am J Cardiol. 2019;123(9):1532–7. https://doi.org/10.1016/j.amjcard.2019.02.006.CrossRefPubMedPubMedCentral

78.

Hayes D Jr, Tumin D, Budev MM, Tobias JD, St John RC, Kukreja J. Adverse outcomes associated with pulmonary hypertension in chronic obstructive pulmonary disease after bilateral lung transplantation. Respir Med. 2017;128:102–8. https://doi.org/10.1016/j.rmed.2017.04.010.CrossRefPubMed

79.

Diamond JM, Lee JC, Kawut SM, Shah RJ, Localio AR, Bellamy SL, et al. Clinical risk factors for primary graft dysfunction after lung transplantation. Am J Respir Crit Care Med. 2013;187(5):527–34. https://doi.org/10.1164/rccm.201210-1865OC.CrossRefPubMedPubMedCentral

80.

Julliard WA, Meyer KC, De Oliveira NC, Osaki S, Cornwell RC, Sonetti DA, et al. The presence or severity of pulmonary hypertension does not affect outcomes for single-lung transplantation. Thorax. 2016;71(5):478–80. https://doi.org/10.1136/thoraxjnl-2015-207354.CrossRefPubMed

81.

de Perrot M, Granton JT, McRae K, Cypel M, Pierre A, Waddell TK, et al. Impact of extracorporeal life support on outcome in patients with idiopathic pulmonary arterial hypertension awaiting lung transplantation. J Heart Lung Transplant. 2011;30(9):997–1002. https://doi.org/10.1016/j.healun.2011.03.002.CrossRefPubMed

82.

Javidfar J, Brodie D, Iribarne A, Jurado J, Lavelle M, Brenner K, et al. Extracorporeal membrane oxygenation as a bridge to lung transplantation and recovery. J Thorac Cardiovasc Surg. 2012;144(3):716–21. https://doi.org/10.1016/j.jtcvs.2012.05.040.CrossRefPubMed

83.

Dellgren G, Riise GC, Sward K, Gilljam M, Rexius H, Liden H, et al. Extracorporeal membrane oxygenation as a bridge to lung transplantation: a long-term study. Eur J Cardiothorac Surg. 2015;47(1):95–100; discussion. https://doi.org/10.1093/ejcts/ezu112.CrossRefPubMed

84.

Granton J, Mercier O, De Perrot M. Management of severe pulmonary arterial hypertension. Semin Respir Crit Care Med. 2013;34(5):700–13. https://doi.org/10.1055/s-0033-1356460.CrossRefPubMed

85.

Abrams DC, Brodie D, Rosenzweig EB, Burkart KM, Agerstrand CL, Bacchetta MD. Upper-body extracorporeal membrane oxygenation as a strategy in decompensated pulmonary arterial hypertension. Pulm Circ. 2013;3(2):432–5. https://doi.org/10.4103/2045-8932.113178.CrossRefPubMedPubMedCentral

86.

Olsson KM, Simon A, Strueber M, Hadem J, Wiesner O, Gottlieb J, et al. Extracorporeal membrane oxygenation in nonintubated patients as bridge to lung transplantation. Am J Transplant. 2010;10(9):2173–8. https://doi.org/10.1111/j.1600-6143.2010.03192.x.CrossRefPubMed

87.

Ius F, Kuehn C, Tudorache I, Sommer W, Avsar M, Boethig D, et al. Lung transplantation on cardiopulmonary support: venoarterial extracorporeal membrane oxygenation outperformed cardiopulmonary bypass. J Thorac Cardiovasc Surg. 2012;144(6):1510–6. https://doi.org/10.1016/j.jtcvs.2012.07.095.CrossRefPubMed

88.

Keogh AM, Mayer E, Benza RL, Corris P, Dartevelle PG, Frost AE, et al. Interventional and surgical modalities of treatment in pulmonary hypertension. J Am Coll Cardiol. 2009;54(1 Suppl):S67–77. https://doi.org/10.1016/j.jacc.2009.04.016.CrossRefPubMed

89.

Punnoose L, Burkhoff D, Rich S, Horn EM. Right ventricular assist device in end-stage pulmonary arterial hypertension: insights from a computational model of the cardiovascular system. Prog Cardiovasc Dis. 2012;55(2):234–43.e2. https://doi.org/10.1016/j.pcad.2012.07.008.CrossRefPubMed

90.

Patil NP, Mohite PN, Reed A, Popov AF, Simon AR. Modified technique using Novalung as bridge to transplant in pulmonary hypertension. Ann Thorac Surg. 2015;99(2):719–21. https://doi.org/10.1016/j.athoracsur.2014.09.061.CrossRefPubMed

91.

Fischer S, Simon AR, Welte T, Hoeper MM, Meyer A, Tessmann R, et al. Bridge to lung transplantation with the novel pumpless interventional lung assist device NovaLung. J Thorac Cardiovasc Surg. 2006;131(3):719–23. https://doi.org/10.1016/j.jtcvs.2005.10.050.CrossRefPubMed

Titel: Pulmonary Hypertension and Thoracic Surgery: Impact and Treatment Options
verfasst von: Loren Francis
Stephanie Whitener
Jared McKinnon
George Whitener
Publikationsdatum: 11.11.2019
Verlag: Springer US
Erschienen in: Current Anesthesiology Reports / Ausgabe 4/2019
Elektronische ISSN: 2167-6275
DOI: https://doi.org/10.1007/s40140-019-00360-x

Neu im Fachgebiet AINS

23.04.2024 | Appendizitis | Nachrichten

Update AINS

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

hier abonnieren

Springer Medizin

Pulmonary Hypertension and Thoracic Surgery: Impact and Treatment Options

Abstract

Purpose of Review

Recent Findings

Summary

Neu im Fachgebiet AINS

Hinter dieser Appendizitis steckte ein Erreger

Ärztliche Empathie hilft gegen Rückenschmerzen

Mehr Schaden als Nutzen durch präoperatives Aussetzen von GLP-1-Agonisten?

S3-Leitlinie zu Pankreaskrebs aktualisiert

Update AINS

Springer Medizin

Abstract

Purpose of Review

Recent Findings

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2019

Positive End-Expiratory Pressure (PEEP), Tidal Volume, or Alveolar Recruitment: Which One Does Matter in One-Lung Ventilation?

Which Anesthesia Regimen Should Be Used for Lung Surgery?

Experimental Data on the Pulmonary Effects of Remote Ischemic Preconditioning

Outcomes in Pain Clinical Research: What Really Matters for Patients?

The Role of Extracorporeal Life Support in Thoracic Surgery

Correction to: Quadratus Lumborum Block: a Technical Review

Neu im Fachgebiet AINS

Hinter dieser Appendizitis steckte ein Erreger

Ärztliche Empathie hilft gegen Rückenschmerzen

Mehr Schaden als Nutzen durch präoperatives Aussetzen von GLP-1-Agonisten?

S3-Leitlinie zu Pankreaskrebs aktualisiert

Update AINS